Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study

Chest

Volumn 114, Issue 1, 1998, Pages 120-130

  DeAbate, C Andrew ^a   Henry, Dan ^b   Bensch, George ^c   Jubran, Amal ^d   Chodosh, Sanford ^e   Harper, Lisa ^f   Tipping, Diane ^f   Talbot, George H ^f  

^a Medical Research Centers   (United States)

^b Foothill Family Clinic   (United States)

^c Allergy Immunology and Asthma Group Inc   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e VA Outpatient Clinic   (United States)

^f SANOFI   (France)

Author keywords

Acute bacterial exacerbations of chronic bronchitis; Drug therapy; Ofloxacin; Sparfloxacin

Indexed keywords

ANTIBIOTIC AGENT; OFLOXACIN; SPARFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031815318     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.114.1.120     Document Type: Article

References (42)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am J Respir Crit Care Med 1995; 152:S77-120
2. Woolcock AJ. Epidemiology of chronic airways disease. Chest 1989; 96(suppl):302S-06S
3. Chodosh S. Treatment of acute bacterial exacerbations of chronic bronchitis: state of the art. Am J Med 1991; 91(suppl 6A):87-92
4. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: John Wiley, 1990; 529-31
5. Rodnick JE, Gude JK. The use of antibiotics in acute bronchitis and acute bacterial exacerbations of chronic bronchitis. West J Med 1988; 149:347-51
6. Ellner JJ. Management of acute and chronic respiratory tract infections. Am J Med 1988; 85(suppl 3A):2-5
7. Baquero F, Canton R. In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. J Antimicrob Chemother 1996; 37(suppl A):1-18
8. Isada CM. Pro: antibiotics for chronic bronchitis with exacerbations. Semin Respir Infect 1993; 8:243-53
9. Ball P, Tilltoson G, Wilson R. Chemotherapy for chronic bronchitis: controversies. Presse Med 1995; 24:189-94
10. Cunha B. Newer antimicrobial agents for use in acute bacterial exacerbations in chronic bronchitis. Adv Ther 1996; 13:313-23
11. Canton R, Peman J, Jimenez, et al. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother 1992; 36:558-65
12. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99(suppl 6B):3-7
13. Honeybourne D, Greaves I, Baldwin DR. The concentration of sparfloxacin in lung tissues after single and multiple doses. Int J Antimicrob Agents 1994; 4:151-55
14. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996; 37(suppl):57-63
15. Nakashima M, Uematsu T, Takiguchi Y. Phase I study of pyridone carboxylic acid antibacterial agent, sparfloxacin. Rinsho-Yakuri 1991; 7:1639-84
16. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother 1996; 37(suppl):A41-55
17. Johnson RD, Wilson J, Talbot G, et al. The effect of sparfloxacin on the steady-state pharmacokinetics of digoxin in healthy male volunteers. Pharm Res 1994; 11(10 suppl):S-429
18. Jonkman J, Crijns H, Surtees M. Phase I, open study of the effect of sparfloxacin (400 mg for 1 day followed by 200 mg for a further 6 days) on warfarin pharmacodynamics in 10 healthy volunteers. (Protocol AT-113). July 2, 1993; unpublished data; Rhône-Poulenc Rorer
19. Gries JM, Honorato J, Taburet AM, et al. Cimetidine does not alter sparfloxacin pharmacokinetics. Int J Clin Pharmacol Ther 1995; 33:585-87
20. Shimada J, Saito A, Shiba K, et al. Pharmacokinetics and clinical studies on sparfloxacin. Chemotherapy 1991; 39: 234-44
21. Jaillon P, Morganroth J, Brumpt I, et al. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother 1996; 37(suppl): 161-67
22. Woods GL, Washington JA. The clinician and the microbiology laboratory. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995; 169-99
23. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 3rd ed; approved standard. NCCLS Document M7-A3 (vol 13), No. 25, 1993
24. Performance standards for antimicrobial disk susceptibility tests. 5th ed; approved standard. NCCLS Document M2-A5 (vol 13), No. 24, 1993
25. Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996; 174:986-93
26. Chodosh S. Use of quinolones for the treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med 1991; 91(suppl 6A):93-100
27. Hara K, Kobayashi H, Tanimoto H, et al. A multicenter double-blind comparative study of sparfloxacin and ofloxacin in the treatment of chronic respiratory tract infections [abstract 878]. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Sept 29-Oct 2, 1991; 245
28. Soejima R, Hara K. Clinical response of sparfloxacin in respiratory tract infections. Drugs 1993; 45(suppl 3):405-06
29. Ortqvist A, Valtonen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 1996; 110:1499-1506
30. Saito A, Katsu M, Saito A, et al. Ofloxacin in respiratory tract infections: a review of the results of clinical trials in Japan. Drugs 1987; 34(suppl 1):83-89
31. Grassi C, Grassi G, Mangiarotti P. Clinical efficacy of ofloxacin in lower respiratory tract infections. Drugs 1987; 34(suppl 1):80-82
32. Rademaker CMA, Sips AP, Beumer HM, et al. A double-blind comparison of low dose ofloxacin and amoxycillin/ clavulanic acid in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1990; 26(suppl D):75-81
33. Soejima R, Niki Y, Kishomoto T, et al. Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections. Drugs 1995; 49(suppl 2):257-59
34. Carbon C. Quinolones in the treatment of lower respiratory tract infections in adult patients. Drugs 1993; 45(suppl 3): 91-97
35. Isada CM, Stoller JK. Chronic bronchitis: role of antibiotics. In: Niederman MS, Sarosi GA, Glassroth J, eds. Respiratory infections. Philadelphia: WB Saunders, 1994; 621-31
36. Marrie TJ, Peeling RW, Fine MJ. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101:508-15
37. Lietman PS. Fluoroquinolone toxicities: an update. Drugs 1995; 42(suppl 2):159-63
38. Shimada J, Nogita T, Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 1993; 25:358-69
39. Tulkins P. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10:100-06
40. Couraud L, Fourtillan JB, Saux MC, et al. Diffusion of ofloxacin into human lung tissue. Drugs 1987; 34(suppl 1):37-38
41. Levofloxacin package insert. Raritan, NJ: Ortho-McNeil Pharmaceutical, 1997
42. Perea EJ. Ofloxacin concentrations in tissues involved in respiratory tract infections. J Antimicrob Chemother 1990; 26(suppl D):55-60